Hello. Sign In
Standards Store




Myelodysplastic Syndromes: Pathobiology and Clinical Management

2008 Edition, December 12, 2008

Complete Document



Detail Summary

Active, Most Current

EN
Additional Comments:
ISBN: 978-1-4200-7440-6
Format
Details
Price (USD)
Print
Backordered
$330.00
Add to Cart

Product Details:

  • Revision: 2008 Edition, December 12, 2008
  • Published Date: December 12, 2008
  • Status: Active, Most Current
  • Document Language: English
  • Published By: CRC Press (CRC)
  • Page Count: 570
  • ANSI Approved: No
  • DoD Adopted: No

Description / Abstract:

Preface to the Second Edition

The landscape of the myelodysplastic syndromes (MDS) has changed considerably since the first edition of Myelodysplastic Syndromes: Pathobiology and Clinical Management, edited by venerable MDS morphologist Dr. John Bennett, was published in 2002. In these 6 years since that text appeared, the Food and Drug Administration in the United States has approved three new medications for MDS indications (azacitidine in 2004, lenalidomide in 2005, and decitabine in 2006), and clinicians and morphologists have grown comfortable enough with the 2001 disease re-classification by the World Health Organization to demand a revision. MDS is now captured by the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute, promising more accurate epidemiological numbers. Supportive care strategies were altered by increased realization of the potential harm of chronic transfusional iron overload in MDS, by approval of an oral iron chelator, deferasirox, and by the introduction of a long-acting erythropoiesis stimulating agent, darbepoetin alfa. The range of patients suffering from MDS who are eligible for hematopoietic stem cell transplantation has expanded, as nonmyeloablative approaches allow older and sicker patients to be considered for this procedure.

Our understanding of the pathobiology of MDS has perhaps not kept up with the myeloproliferative disorders, where the landmark discovery of the common JAK2 V617F mutation in 2005 led to major changes in diagnosis and disease classification. Still, there have been some exciting advances, with much hope for the near future as biotechnology techniques continue to get better, cheaper, and faster. Global genomic approaches (e.g., cDNA expression arrays, arraybased comparative genomic hybridization, and single nucleotide polymorphism arrays) have yielded new insights into gene expression patterns in MDS; several provocative findings from these global approaches promise to stimulate new lines of research. The role of abnormal mitochondrial ferritin accumulation and other mitochondrial metabolic anomalies in MDS is now better appreciated, and other disease-associated alterations, such as abnormalities of B lymphocyte populations in MDS, are also receiving increased attention.

This edition of Myelodysplastic Syndromes: Pathobiology and Clinical Management again assembles a team of knowledgeable contributors chosen from among the world's leading MDS authorities for their understanding of pathogenesis, diagnostic techniques, and clinical management strategies in MDS. After an introductory chapter on the history of the nosologic concept of MDS, the first major section of the book focuses on MDS epidemiology and biology, followed by a section on diagnosis, classification, and prognosis, and concluding with a section on MDS therapy. New areas of concentration in this book include a chapter on del(5q) and 5q syndrome—a group of conditions that has assumed increasing importance because of the striking clinical success with lenalidomide therapy—as well as two chapters on lenalidomide and on the reborn DNA methyltransferase inhibiting nucleoside analogs.We are also fortunate to be able to include newchapters devoted to the challenging diagnosis of chronic myelomonocytic leukemia and other MDS cases with myeloproliferative features, global genomic approaches to MDS, the role of mitochondria in MDS, and the potential importance of iron overload in MDS. In addition, all the other chapters from the first edition have been thoroughly updated; in some cases, merging chapters or shifting the topical focus as dictated by the evolution of the field has also been done.

The growing interest in MDS in the medical and pharmaceutical communities is attested to by the increased numbers of attendees at the biennial international symposia organized by the MDS Foundation, as well as the packed crowds that now routinely fill MDS sessions at large general hematology meetings such as the annual meeting of the American Society of Hematology and the congresses of the European Hematology Association. Therefore, it seems timely to bring out a new edition of this text, which the contributors and I believe will be of value for investigators engaged in MDS research, clinicians diagnosing and caring for patients with MDS, and interested students of this challenging and puzzling group of hematopoietic failure states.